Member Info for HarChris

Q18, how about Choose British, Choose PCR, Choose Novacyt, Choose SNPsig, Choose Life?

If i remember correctly UAE was named in an rns as one of the countries the two-gene test was aimed at?

What a strange comment, I think I am transparent yeah, you make it out to be a bad thing.

I shared on here that I bought back in last week... and if it drops more I'll buy even more. Is that deramping?! I don't want it to fall, I'm invested. If it does it it means I have a higher amount of my portfolio in ncyt than I planned. Not ideal but shouldn't complain.

VanV I'm very supportive of you as you know and consider you the most important poster on this bb... but to be honest every time you respond to a comment about LFTs or 'SLFTs' it puts it back avacta and co back into focus. Perhaps if you abstained from responding to every criticism you get on here from now on there would be more harmony on the board?!

Besides possibly dropping first thing Monday if no news, I don't think this can go much lower. Traders like Myles McNulty and a couple of notable folk on twitter started buying in the 7s and see a sharp reversal on the cards. If that sort of trader is in at these levels I don't see it going much lower. I'm planning to buy more first thing.

https://www.telegraph.co.uk/global-health/science-and-disease/suppressed-seasonal-flu-may-come-back-vengeance-next-winter/

£5?! £350m mcap?! Would be amazed.

I'm looking to buy more if no news early doors and wondered if there was a chance of it dipping into the 6s, to be honest I don't think I'll risk waiting. £5? Imo no way.

From the little I understand interferons are one of the key tools the body has to fight off viruses. We're soon to find out how effective sng001 is against this particular coronavirus and then naturally it would suggest some read across to other viruses, especially other coronaviruses. Of course it's not a given that it would be effective against a virus as deadly as Ebola or MERS just because it had great therapeutic benefits against Sars CoV 2 but it would certainly give some hope in that area.

How good do the results have to be for all the other uses/stockpiling to come into focus? In my head there's a huge difference between positive results that leads to an EUA and stellar results that match p2. Is that a fair assessment?

I'm planning to have money ready so if results are exceptional I might be one of the lucky ones to take shares off the likes of Org at £3/£4.

Q4 2021 is a little disappointing to see but that will refer to the p3 of the p2/p3. My guess would be Q2 for the p2 arm and we got to hope results are profound enough to get EUA from that/home trial.

It's a punt in as much as any non-revenue generating AIM company is but you're making it out to be a coin toss, a 50/50 bet. Pre-p2 perhaps but now with all the science stacking up in SNG's favour and the money and backing to get it to market if it works, no not the punt you are making it out to be.

The problem is once a trading pattern has formed it is difficult to break it in the short and medium term.

I was just sharing the p/e definition but I agree it's incredibly cheap. There seems to be many of us expecting a further fall Monday, if it does hit £7 we're bound to see a 50% uplift in the not too distant future, maybe closer to 100% with positive news...

I make it mcap £524m and profit ~£150m (won't know until full year results are published). Gives a p/e of about 3.5.

We don't have a p/e of 1.99 roley. P/e ratios use net profit not EBITDA - I imagine after tax you're looking at something like £150m (still amazing). Also you can't really give a p/e ratio based on one exceptional year.

If somehow ncyt are still making £150m net profit a year in 2023 these shares will be worth £70. Is that possible? Many on here believe it to be!

crl, imo this will attack the £14 target if there is clear evidence that 2021 sales are going to eclipse 2020s. That could be a major US contract, DHSC contract extension or new larger longer term contract, or even a Q1 trading update that shows an incredible start to the year.

Has there been any mention of switching to quarterly updates/ do you think it's likely? The half yearly does seem a bit unusual for an AIM company this size, even the likes of Boohoo and ASOS do regular trading updates throughout the year. These first three months are bound to at least match the last half year so we're talking £100m+ and an extra £70m in the kitty...

Agree with gggg, near term demand for LFT will outstrip PCR but the need to test in clinical settings is here indefinitely.

I don't have such lofty hopes for this share as some on here but I do think now, at this price, the R/R is exceptional. It's not so much the reward being that great (it might), it's that the risk is so low. I try to picture buying and holding for two years and forecasting where the share price will be.

To justify this valuation they'll need to be making about £20m a year in two years from now having reinvested the windfall. I mean, it's highly likely they'll be making that from covid alone. On top of that wider economic factors such as another credit crunch won't hurt them and the future for diagnostics is rosey.

In other words, it's pretty damn hard to lose money investing at this level and the upside is unknown with potential to multibag.

Yes. May well have a good product, won't get it it to market for covid or similar that's for sure.
I think they were trialling in Australia but there just weren't enough cases, tried to pivot to another country (Indonesia?) and eventually gave up on this route.